222 related articles for article (PubMed ID: 19878083)
1. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
[No Abstract] [Full Text] [Related]
2. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
5. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
6. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
7. Drugs offer new hope for patients with CML who are resistant to imatinib.
Oestreicher P
ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
[No Abstract] [Full Text] [Related]
8. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
10. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
11. Circumventing resistance to kinase-inhibitor therapy.
Druker BJ
N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
[No Abstract] [Full Text] [Related]
12. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
13. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
[No Abstract] [Full Text] [Related]
14. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
[TBL] [Abstract][Full Text] [Related]
16. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
17. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
18. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
[TBL] [Abstract][Full Text] [Related]
19. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
20. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
